The clearance of antipyrine and indocyanine green in normal subjects and in patients with chronic lever disease.
about
Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurementsPreclinical lymphatic imaging.Quantitative assessment of the multiple processes responsible for bilirubin homeostasis in health and disease.Antipyrine kinetics in liver disease and liver transplantation.Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis.Antipyrine clearance per unit volume liver: an assessment of hepatic function in chronic liver disease.Verapamil favorably influences hepatic microvascular exchange and function in rats with cirrhosis of the liver.In vivo fluorescence imaging: a personal perspective.Drug metabolism and liver disease: a drug-gene-environment interaction.Protein binding and kinetics of drugs in liver diseases.Plasma renin substrate sensitivity to oestrogens and oestrogen metabolism in cirrhosis.Disease as one of many variables affecting drug disposition and response: alterations of drug disposition in liver disease.Small animal model of weightlessness for pharmacokinetic evaluation.Decreased uptake of taurocholate and ouabain by hepatocytes isolated from cirrhotic rat liver.Hepatic elimination of indocyanine green with special reference to distribution kinetics and the influence of plasma protein binding.Fasting plasma caffeine concentration. A guide to the severity of chronic liver disease.Effect of upper abdominal surgery and cirrhosis upon the pharmacokinetics of methohexital.
P2860
Q26739820-D0EAE20B-EC4A-4800-87FA-097066586E79Q30465292-91C1B0B3-2DC0-438C-88C6-36D13A3DE304Q34155271-B9D27DF7-0C9F-41ED-86A3-3B18ADB353CAQ34198161-446F79B7-E1A4-4366-B56A-AEE476935D61Q34346052-2871FC10-55F5-49F5-A688-A494A63DC7B6Q34475680-FD37B1D4-16A2-4806-A88C-98532B62D8EAQ34533948-D52815FE-107D-4277-90FB-B7B152C2B372Q34966518-F0AB9117-7656-4A2D-B17A-C4E7F771022DQ39037269-0682CDE6-0B52-4E1E-9692-849A33DAA67EQ39620831-780F4C8D-FCC7-4C52-8860-6761AFD7C9F7Q39623138-C6102C2B-1170-445E-B221-EA52671F7CF8Q39780230-2778941F-5C47-4625-A2B6-C0792201F953Q40701397-519C3BD9-1F40-4810-9898-9729E3A1D0B0Q41478880-FF118296-52D1-419B-850A-88D86ED0AB92Q47722814-8A227E91-3F36-4A61-BDE2-9D0FA6E48F3EQ51636261-E7778970-19F3-4610-8325-2AB2031B93C9Q51716779-789E34E6-35AE-40E5-83CF-C9BD405D2E50
P2860
The clearance of antipyrine and indocyanine green in normal subjects and in patients with chronic lever disease.
description
1976 nî lūn-bûn
@nan
1976年の論文
@ja
1976年論文
@yue
1976年論文
@zh-hant
1976年論文
@zh-hk
1976年論文
@zh-mo
1976年論文
@zh-tw
1976年论文
@wuu
1976年论文
@zh
1976年论文
@zh-cn
name
The clearance of antipyrine an ...... ts with chronic lever disease.
@en
The clearance of antipyrine an ...... ts with chronic lever disease.
@nl
type
label
The clearance of antipyrine an ...... ts with chronic lever disease.
@en
The clearance of antipyrine an ...... ts with chronic lever disease.
@nl
prefLabel
The clearance of antipyrine an ...... ts with chronic lever disease.
@en
The clearance of antipyrine an ...... ts with chronic lever disease.
@nl
P2093
P356
P1476
The clearance of antipyrine an ...... ts with chronic lever disease.
@en
P2093
P356
10.1002/CPT197620181
P407
P577
1976-07-01T00:00:00Z